Clinical trial · Observational
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
A Non-interventional Observational Study of Infectious Complications in Cancer Patients
NCT01622595CI-TRIAL-00019585withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Principal Investigator has left the institution.
Summary
Brief summary (as posted)
OBSERVATIONAL STUDY OF INFECTIOUS COMPLICATIONS IN CANCER PATIENTS
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aspergillosis | — | UNRESOLVED | — |
| Candidemia | — | UNRESOLVED | — |
| C. Difficile | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To study the incidence, risk factors, clinical presentation, diagnosis and prognostic factors of infectious complications in cancer patients
- timeFrame
- 3 years
- description
- To study the incidence, risk factors, clinical presentation, diagnosis and prognostic factors of infectious complications in cancer patients
Secondary outcomes (1)
- measure
- incidence
- timeFrame
- 3 years
- description
- To determine the overall incidence of different infections, including bacterial, fungal and viral infections in cancer patients receiving chemotherapy and / or hematopoietic stem cell transplantation. * To describe the natural history of such infections in cancer patients. * To monitor the adherence of Myeloma institute for research and therapy(MIRT) health care workers to the MIRT standard operational procedures (SOPs) * To identify risk factors for the development of specific infections. * To validate surrogate markers as early diagnostic tools for various infections.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * cancer patients with Infections Exclusion Criteria: * No Infections
References
Publications (0)
Data not yet available
No reference posted for this study.